Almirall (ES:ALM) has released an update. Almirall, S.A. is set to present and discuss its financial results for the first ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

Having been in development by Almirall and Eli Lilly and Company for moderate to severe AD, recent findings from a phase 3 trial for the first time have shown year-long (52-week) management of ...

Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month ...

Almirall has put patients’ friends and family at the heart of its activities for the 2024 World Psoriasis Day, ...

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

BARCELONA, Spain, July 22, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued ...

BARCELONA, Spain, October 15, 2024--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the ...

The third edition of ImmunoSkin underscored Almirall’s commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for ...